Literature DB >> 2201299

Kinetic modelling of the response of Plasmodium falciparum to chloroquine and its experimental testing in vitro. Implications for mechanism of action of and resistance to the drug.

T G Geary1, A D Divo, J B Jensen, M Zangwill, H Ginsburg.   

Abstract

The antimalarial mode of action of chloroquine (CQ) has been investigated in great detail in recent years, but the overall mechanism is still controversial. Instead of further probing the molecular aspects of partial reactions, a model based on the weak base properties of CQ and its delta pH-driven accumulation in acid parasite compartments has been devised, and the integrated response of the parasite to the drug under different experimental conditions has been assayed to verify the validity of the model. Factors such as inoculum size (parasitemia.hematocrit) and medium pH were altered using CQ-sensitive (FCC1) and -resistant (FCR3, VNS) isolates of Plasmodium falciparum. Experimental results were in full agreement with the predictions of the model, implying that therapeutic concentrations of CQ do not raise the pH of the food vacuole, i.e. that alkalinization of the acid parasite compartments is an insufficient explanation for the antimalarial activity of CQ, and that there is no need to invoke an active QC efflux pump to explain drug resistance. Calculations based on the model and the experimental data demonstrate that resistance to CQ is correlated with higher pH and/or higher resistance of the intracellular target to the drug concentration in the parasite food vacuole. The data also have implications for the design and interpretation of in vitro CQ inhibitory tests.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201299     DOI: 10.1016/0006-2952(90)90302-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates β-hematin formation with an unusually low activation energy.

Authors:  Anh N Hoang; Rebecca D Sandlin; Aneesa Omar; Timothy J Egan; David W Wright
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

2.  In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs.

Authors:  Timothy M E Davis; Juliana Hamzah; Kenneth F Ilett; Harin A Karunajeewa; John C Reeder; Kevin T Batty; Sara Hackett; P Hugh R Barrett
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component.

Authors:  S R Hawley; P G Bray; P M O'Neill; D J Naisbitt; B K Park; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials.

Authors:  P Loria; S Miller; M Foley; L Tilley
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

5.  Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro.

Authors:  S R Hawley; P G Bray; M Mungthin; J D Atkinson; P M O'Neill; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 6.  Scoping insight on antiviral drugs against COVID-19.

Authors:  Ahmed S Ali; Ibrahim M Ibrahim; Abdulhadi S Burzangi; Ragia H Ghoneim; Hanin S Aljohani; Hamoud A Alsamhan; Jehan Barakat
Journal:  Arab J Chem       Date:  2021-08-16       Impact factor: 5.165

7.  Evaluation of pH during cytostomal endocytosis and vacuolar catabolism of haemoglobin in Plasmodium falciparum.

Authors:  Nectarios Klonis; Olivia Tan; Katherine Jackson; Daniel Goldberg; Michael Klemba; Leann Tilley
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

8.  Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia.

Authors:  Suwanna Chaorattanakawee; Stuart D Tyner; Chanthap Lon; Kritsanai Yingyuen; Wiriya Ruttvisutinunt; Siratchana Sundrakes; Piyaporn Sai-gnam; Jacob D Johnson; Douglas S Walsh; David L Saunders; Charlotte A Lanteri
Journal:  Malar J       Date:  2013-07-12       Impact factor: 2.979

Review 9.  Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Authors:  Usman Arshad; Henry Pertinez; Helen Box; Lee Tatham; Rajith K R Rajoli; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steve P Rannard; Paul M O'Neill; Ghaith Aljayyoussi; Shaun H Pennington; Stephen A Ward; Andrew Hill; David J Back; Saye H Khoo; Patrick G Bray; Giancarlo A Biagini; Andrew Owen
Journal:  Clin Pharmacol Ther       Date:  2020-06-14       Impact factor: 6.903

10.  The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance.

Authors:  James M Murithi; Ioanna Deni; Charisse Flerida A Pasaje; John Okombo; Jessica L Bridgford; Nina F Gnädig; Rachel L Edwards; Tomas Yeo; Sachel Mok; Anna Y Burkhard; Olivia Coburn-Flynn; Eva S Istvan; Tomoyo Sakata-Kato; Maria G Gomez-Lorenzo; Annie N Cowell; Kathryn J Wicht; Claire Le Manach; Gavreel F Kalantarov; Sumanta Dey; Maëlle Duffey; Benoît Laleu; Amanda K Lukens; Sabine Ottilie; Manu Vanaerschot; Ilya N Trakht; Francisco-Javier Gamo; Dyann F Wirth; Daniel E Goldberg; Audrey R Odom John; Kelly Chibale; Elizabeth A Winzeler; Jacquin C Niles; David A Fidock
Journal:  Cell Chem Biol       Date:  2021-07-06       Impact factor: 9.039

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.